Richard Christopher - 17 Nov 2022 Form 4 Insider Report for INVIVO THERAPEUTICS HOLDINGS CORP.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 17 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Nov 2022, 16:05:37 UTC
Next SEC filing: 05 Sep 2024
Source filing: View source filing
Reporting owner signature: /s/ Heather Hamel, Attorney-in-fact

Key filing fact

Richard Christopher filed Form 4 for INVIVO THERAPEUTICS HOLDINGS CORP. on 21 Nov 2022.

Key facts

This page summarizes Richard Christopher's Form 4 filing for INVIVO THERAPEUTICS HOLDINGS CORP..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Nov 2022, 16:05.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVIV transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +20,800
Change %
Price: $0.000000
Shares after: 20,800
Date: 17 Nov 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,800
Exercise price: $2.50
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on November 17, 2022. The shares underlying the option vest over two years, with 50% of the shares vesting on November 17, 2023 and the remaining shares vesting on November 17, 2024.